Trial Profile
Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Brain cancer; Clear cell sarcoma; CNS cancer; Diffuse intrinsic pontine glioma; Ependymoma; Glioma; Medulloblastoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Acronyms AflacST1501
- 24 Oct 2023 Status changed from recruiting to completed.
- 18 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 18 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.